Malignant Mesothelioma
Malignant mesothelioma (MM) is a rare and aggressive cancer, related to chronic inflammation and oxidative stress caused mainly by exposure to asbestos. Although this mineral has been banned for decades in many countries, epidemiologists predict the MM epidemic will last past 2040, raising many conc...
Saved in:
HerausgeberIn: | |
---|---|
Sonstige: | |
Year of Publication: | 2021 |
Language: | English |
Physical Description: | 1 electronic resource (328 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993546034004498 |
---|---|
ctrlnum |
(CKB)5400000000042299 (oapen)https://directory.doabooks.org/handle/20.500.12854/77046 (EXLCZ)995400000000042299 |
collection |
bib_alma |
record_format |
marc |
spelling |
L. Pouliquen, Daniel edt Malignant Mesothelioma Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021 1 electronic resource (328 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Malignant mesothelioma (MM) is a rare and aggressive cancer, related to chronic inflammation and oxidative stress caused mainly by exposure to asbestos. Although this mineral has been banned for decades in many countries, epidemiologists predict the MM epidemic will last past 2040, raising many concerns in public health given its late diagnosis, dismal prognosis, and lack of current efficient therapies.To deal with this situation, important breakthroughs have recently been made in the understanding of MM’s complex biology and the carcinogenic process of the different patterns of the disease. Examples of these include the development of new biomarkers and the deciphering of gene–environment interactions, molecular mechanisms of invasiveness, deregulated pathways, altered expression of miRNAs, DNA damage repair, or metabolic profile. From now on, MM’s aggressive and chemoresistant character appears linked to a polyclonal malignancy, and heterogeneity in molecular alterations.Given these improvements, new therapeutic targets are being explored to solve the double challenge faced by clinicians. The first is to reduce tumor development and its wasting consequences as soon as possible, without resistance and with limited toxicity. The second is to stimulate the recognition of tumor cells by the induction of a specific immune response. This Special Issue will highlight all these aspects. English Medicine bicssc well-differentiated papillary mesothelioma WDPM malignant mesothelioma DNA sequencing mutation mesothelioma tumor suppressor targeted therapy immunotherapy biomarkers proteomics macrophage-capping protein fatty acid-binding protein laminin subunit beta-2 selenium-binding protein 1 carcinogenesis malignant pleural mesothelioma asbestos exposure DNA methylation lymphocyte-to-monocyte ratio epigenome-wide analysis survival analysis metabolomics radiotherapy cancers inflammation infiltrating immune cells prognostic biomarker predictive biomarker immune therapy VATS extrapleural pneumonectomy pleurectomy decortication therapy response survival FDG PET-CT mesothelium oxidative stress redox-sensitive factors asbestos carbon nanotubes protein-protein interactions systems biology network analysis drug repurposing pleural mesothelioma gene expression immunogenicity sarcomatoid epithelioid first line meta-analysis systematic review MPM lurbinectedin DNA damage response histotype Hippo pathway NF2 BAP1 CDKN2A PTCH1 SETD2 MTAP liquid biopsies circulating tumor DNA plasma cancer-specific mutations genomics cancer biomarkers tumor microenvironment tumor-associated macrophages dendritic cells immunohistochemistry interaction analysis pleural effusion 3-0365-2368-5 3-0365-2367-7 Kopecka, Joanna edt L. Pouliquen, Daniel oth Kopecka, Joanna oth |
language |
English |
format |
eBook |
author2 |
Kopecka, Joanna L. Pouliquen, Daniel Kopecka, Joanna |
author_facet |
Kopecka, Joanna L. Pouliquen, Daniel Kopecka, Joanna |
author2_variant |
p d l pd pdl j k jk |
author2_role |
HerausgeberIn Sonstige Sonstige |
title |
Malignant Mesothelioma |
spellingShingle |
Malignant Mesothelioma |
title_full |
Malignant Mesothelioma |
title_fullStr |
Malignant Mesothelioma |
title_full_unstemmed |
Malignant Mesothelioma |
title_auth |
Malignant Mesothelioma |
title_new |
Malignant Mesothelioma |
title_sort |
malignant mesothelioma |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2021 |
physical |
1 electronic resource (328 p.) |
isbn |
3-0365-2368-5 3-0365-2367-7 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT lpouliquendaniel malignantmesothelioma AT kopeckajoanna malignantmesothelioma |
status_str |
n |
ids_txt_mv |
(CKB)5400000000042299 (oapen)https://directory.doabooks.org/handle/20.500.12854/77046 (EXLCZ)995400000000042299 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Malignant Mesothelioma |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField |
_version_ |
1796649071815950336 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04865nam-a2201237z--4500</leader><controlfield tag="001">993546034004498</controlfield><controlfield tag="005">20231214132925.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202201s2021 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000042299</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/77046</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000042299</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">L. Pouliquen, Daniel</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Malignant Mesothelioma</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (328 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Malignant mesothelioma (MM) is a rare and aggressive cancer, related to chronic inflammation and oxidative stress caused mainly by exposure to asbestos. Although this mineral has been banned for decades in many countries, epidemiologists predict the MM epidemic will last past 2040, raising many concerns in public health given its late diagnosis, dismal prognosis, and lack of current efficient therapies.To deal with this situation, important breakthroughs have recently been made in the understanding of MM’s complex biology and the carcinogenic process of the different patterns of the disease. Examples of these include the development of new biomarkers and the deciphering of gene–environment interactions, molecular mechanisms of invasiveness, deregulated pathways, altered expression of miRNAs, DNA damage repair, or metabolic profile. From now on, MM’s aggressive and chemoresistant character appears linked to a polyclonal malignancy, and heterogeneity in molecular alterations.Given these improvements, new therapeutic targets are being explored to solve the double challenge faced by clinicians. The first is to reduce tumor development and its wasting consequences as soon as possible, without resistance and with limited toxicity. The second is to stimulate the recognition of tumor cells by the induction of a specific immune response. This Special Issue will highlight all these aspects.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">well-differentiated papillary mesothelioma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">WDPM</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">malignant mesothelioma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA sequencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mutation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mesothelioma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor suppressor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeted therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">proteomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">macrophage-capping protein</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">fatty acid-binding protein</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">laminin subunit beta-2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">selenium-binding protein 1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">carcinogenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">malignant pleural mesothelioma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">asbestos exposure</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA methylation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lymphocyte-to-monocyte ratio</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epigenome-wide analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">survival analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metabolomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">radiotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">infiltrating immune cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognostic biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">predictive biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">VATS</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">extrapleural pneumonectomy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pleurectomy decortication</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapy response</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">survival</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">FDG</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PET-CT</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mesothelium</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oxidative stress</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">redox-sensitive factors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">asbestos</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">carbon nanotubes</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">protein-protein interactions</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">systems biology</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">network analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">drug repurposing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pleural mesothelioma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gene expression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunogenicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sarcomatoid</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epithelioid</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">first line</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">meta-analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">systematic review</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MPM</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lurbinectedin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA damage response</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">histotype</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Hippo pathway</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NF2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">BAP1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CDKN2A</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PTCH1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SETD2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MTAP</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">liquid biopsies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">circulating tumor DNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">plasma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer-specific mutations</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genomics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cancer biomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor microenvironment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor-associated macrophages</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dendritic cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunohistochemistry</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">interaction analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pleural effusion</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-2368-5</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-2367-7</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kopecka, Joanna</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">L. Pouliquen, Daniel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kopecka, Joanna</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:35:54 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338142760004498&Force_direct=true</subfield><subfield code="Z">5338142760004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338142760004498</subfield></datafield></record></collection> |